Clinical Drug Experience Knowledgebase

ribociclib (kisqali) (2 trials)

cyclophosphamide (cytoxan) (3 trials)

doxorubicin (Doxil) (3 trials)

epirubicin (ellence) (1 trial)

fluorouracil (efudex) (1 trial)

paclitaxel (taxol) (3 trials)

tamoxifen (nolvadex) (2 trials)

18f-ffnp (1 trial)

abemaciclib (verzenio) (1 trial)

alpelisib (Piqray) (1 trial)

anastrozole (arimidex) (1 trial)

atorvastatin (lipitor) (1 trial)

avelumab (bavencio) (3 trials)

bevacizumab (avastin) (1 trial)

binimetinib (mektovi) (1 trial)

bupropion (wellbutrin) (1 trial)

capecitabine (xeloda) (3 trials)

carboplatin (paraplatin) (3 trials)

cisplatin (platinol) (1 trial)

enzalutamide (xtandi) (1 trial)

estradiol (progynon depot) (1 trial)

exemestane (aromasin) (1 trial)

fludeoxyglucose f-18 (1 trial)

fulvestrant (faslodex) (1 trial)

gemcitabine (gemzar) (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

iniparib (1 trial)

letrozole (femara) (2 trials)

mango (1 trial)

mifepristone (mifeprex) (1 trial)

naltrexone (revia) (1 trial)

oxaloacetate (1 trial)

palbociclib (ibrance) (1 trial)

pembrolizumab (keytruda) (1 trial)

pf-04518600 (1 trial)

progenta (1 trial)

sagopilone (1 trial)

sitagliptin (januvia) (2 trials)

sulforaphane (1 trial)

trastuzumab (herceptin) (6 trials)

utomilumab (2 trials)

vinorelbine (navelbine) (1 trial)

bazedoxifene (Duavee) (1 trial)

conjugated estrogen (1 trial)

Imetelstat (1 trial)

irbinitinib (1 trial)

lapatinib (tykerb) (1 trial)

pertuzumab (perjeta) (1 trial)

docetaxel (taxotere) (1 trial)